had a partial response to the existing regimen. In adult patients with active PsA despite treatment with an IL-12/23i biologic monotherapy, Switch to a TNFi biologic over switching to an IL-17i biologic (PICO 38) Very low Conditional recommendation based on very-low-quality evidence; may consider an IL-17i if the patient has severe psoriasis or contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease. Switch to a TNFi biologic over adding MTX to an IL-12/23i biologic (PICO 36) Very low Conditional recommendation based on very-low-quality evidence; may consider adding MTX in patients in whom the severe psoriasis is not responding to the current therapy, or if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease. Switch to an IL-17i biologic over adding MTX to an IL-12/23i biologic